Head-to-head evidence
Camrelizumab vs Dostarlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Camrelizumab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03134872 · Phase 3 · completed
The study randomly assigned 419 participants to treatment or an active chemotherapy comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Dostarlimab
Marketed by GlaxoSmithKline
NCT03739710 · Phase 2 · completed
An open-label platform master study whose posted primary outcome is only the number of participants randomized across sub-studies; no comparative efficacy result for the dostarlimab-containing regimens is reported on the record. With no usable result and no blinding, this is weak evidence.
Next expected readout: November 2026 · NCT05565378 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camrelizumab's landscape · Dostarlimab's landscape